PD26-TL07 STAT3 inhibitor RGNCY-0110
Per 10 mg
PD26-TL07 is a potent inhibitor of STAT3 which is closely associated to cancer development when its activation is sustained. PD26-TL07 has significant antiproliferative activity against three cell lines (IC50 for HCT-116, SW480 and MDA-MB-2311 were 1.77+0.35 μM, 1.51+0.19 μM and 1.25+0.38 μM respectively). PD26-TL07 also specifically and effectively inhibited STAT3 phosphorylation with little effect on other STATs. PD26-TL07 has an anticancer effect both in vitro and in vivo. It was demonstrated that PD26-TL07 could bind to the SH2 domain of STAT3. these data suggest that PD26-TL07 is a potent anticancer agent targeting STAT3.
Systematic Name: N-(6-((4-chlorobenzyl)amino)-9H-purin-2-yl)benzamide
Mol Wt: 378.82
Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3. Wang, X et al. Eur J Med Chem. 2019 Jun 21;179:218-232.
There are no uploaded files